Management of patients with hepatitis C infection and renal disease
Open Access
- 1 January 2014
- journal article
- review article
- Published by Baishideng Publishing Group Inc. in World Journal of Hepatology
- Vol. 7 (2) , 213-25
Abstract
Hepatitis C virus (HCV) infection in patients with end-stage renal disease (ESRD) is associated with more rapid liver disease progression and reduced renal graft and patients' survival following kidney transplantation. Evaluations and management of HCV in patients with renal disease are challenging. The pharmacokinetics of interferons (IFN), ribavirin (RBV) and some direct acting antiviral (DAA), such as sofosbuvir, are altered in patients with ESRD. With dose adjustment and careful monitoring, treatment of HCV in patients with ESRD can be associated with sustained virological response (SVR) rates nearly comparable to that of patients with normal renal function. DAA-based regimens, especially the IFN-free and RBV-free regimens, are theoretically preferred for patients with ESRD and KT in order to increase SVR rates and to reduce treatment side effects. However, based on the data for pharmacokinetics, dosing safety and efficacy of DAA for patients with severe renal impairment are lacking. This review will be focused on the evaluations, available pharmacologic data, and management of HCV in patients with severe renal impairment, patients who underwent KT, and those who suffered from HCV-related renal disease, according to the available treatment options, including DAA.Keywords
This publication has 102 references indexed in Scilit:
- De NovoFibrillary Glomerulonephritis (FGN) in a Renal Transplant with Chronic Hepatitis CCase Reports in Transplantation, 2013
- 1101 THE EFFECT OF RENAL IMPAIRMENT AND END STAGE RENAL DISEASE ON THE SINGLE-DOSE PHARMACOKINETICS OF PSI-7977Journal of Hepatology, 2012
- Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipientsWorld Journal of Gastroenterology, 2012
- Effect of Kidney Transplantation on Outcomes among Patients with Hepatitis CJournal of the American Society of Nephrology, 2011
- Transient Elastography to Assess Hepatic Fibrosis in Hemodialysis Chronic Hepatitis C PatientsClinical Journal of the American Society of Nephrology, 2011
- Pharmacokinetics and Pharmacodynamics of Peginterferon and Ribavirin: Implications for Clinical Efficacy in the Treatment of Chronic Hepatitis CGastroenterology Clinics of North America, 2010
- Hepatitis C virus–induced cryoglobulinemiaKidney International, 2009
- Treatment of chronic hepatitis C in hemodialysis patientsHepatology, 2008
- Pharmacokinetics of ribavirin in patients with hepatitis C virusBritish Journal of Clinical Pharmacology, 2006
- Extrahepatic manifestations of hepatitis C among United States male veteransHepatology, 2002